2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2007020182v1 18/11/2806    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ballardie, F. W. Search for Related Content PubMed PubMed Citation Articles by Ballardie, F. W.

Quantitative Appraisal of Treatment Options for IgA Nephropathy

Department of Nephrology, Manchester Royal Infirmary, Manchester, United Kingdom

Correspondence: Dr. Francis W. Ballardie, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK. Phone: +44-161-276-4148; Fax: +44-161-276-4129; E-mail: francis.ballardie{at}cmmc.nhs.uk or francisballardie{at}mail.com

IgA nephropathy has an impact on renal health care costs worldwide. The paucity of good clinical trials highlights the uncertainty in determining best treatment and for how long. Ongoing debate still raises questions on why opinions vary but may suggest that current data are not fully understood. The scale of benefit of immunosuppressive drugs in suppressing clinical nephritis or improving outcome is unmatched by use of renin-angiotensin inhibitors alone. By minimizing the use of immunosuppressive drugs, higher risk patients may hazard more ESRD. This review addresses how disparate views have formed, quantifying existing data, to give balance to recommendations.

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673